Tag
This phase 1b study of miricorilant, a selective glucocorticoid receptor modulator, shows significant reductions in liver fat and improvements in liver health markers in patients with presumed metabolic dysfunction-associated steatohepatiti
This review examines the clinical relevance of a ≥30% decrease in VCTE-derived liver stiffness in predicting fibrosis regression in MASH, highlighting modest predictive accuracy and the need for improved biomarkers.
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The MIRNA study evaluated ervogastat, alone and with clesacostat, in patients with biopsy-confirmed MASH and F2-F3 fibrosis, showing combination therapy achieved significant efficacy in resolving MASH without fibrosis worsening and a manage
The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.
HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.
